DR
DRIO.US DarioHealth Corp
- Market cap
- USD 14.2M
- P/E
- -
- P/B
- 0.34x
- ROE
- -46.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DRIO.US undervalued?
Graham numberThe Graham number of DarioHealth Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DarioHealth Corp fundamental analysis
No fundamental analysis for DarioHealth Corp yet.
DarioHealth Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DarioHealth Corp
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and educa…
Full company profileDarioHealth Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DarioHealth Corp annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.80M | 5.17M | 7.39M | 7.56M | 7.58M | 20.5M | 27.7M | 20.4M | 27.0M | 22.4M | 21.4M |
| Gross Profit | -561K | 1.31M | 1.77M | 2.60M | 2.51M | 8.07M | 9.66M | 5.98M | 13.3M | 12.7M | 12.7M |
| Operating Income | -11.1M | -14.4M | -17.7M | -17.7M | -29.9M | -76.5M | -56.8M | -56.2M | -57.7M | -36.7M | -29.1M |
| EBITDA | -10.4M | -14.2M | -17.5M | -17.5M | -29.7M | -70.0M | -55.6M | -54.4M | -37.1M | -35.1M | -26.3M |
| Net Income | -10.9M | -15.7M | -17.8M | -17.7M | -29.4M | -76.8M | -62.2M | -59.4M | -42.7M | -41.7M | -33.4M |
| EPS | -42 | -33 | -15 | -7.83 | -4.94 | -4.63 | -2.63 | -2.09 | -1.06 | -0.84 | -2.77 |
| Balance Sheet | |||||||||||
| Total Assets | 3.87M | 6.96M | 14.1M | 24.6M | 35.4M | 101M | 119M | 96.4M | 119M | 110M | 112M |
| Total Liabilities | 10.4M | 3.02M | 5.16M | 5.68M | 7.26M | 15.2M | 39.2M | 38.2M | 46.9M | 42.2M | 41.2M |
| Shareholders' Equity | -6.54M | 3.94M | 8.93M | 18.9M | 28.2M | 85.5M | 80.0M | 58.1M | 72.0M | 67.9M | 71.3M |
| Cash & Short-term Investments | 1.32M | 3.98M | 11.0M | 20.6M | 28.6M | 36.0M | 49.4M | 36.8M | 28.5M | 26.2M | 31.2M |
| Total Debt | - | - | - | 772K | 532K | 287K | 28.0M | 29.5M | 30.2M | 31.7M | 32.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.38M | -10.6M | -11.5M | -15.7M | -17.7M | -50.4M | -47.8M | -30.4M | -38.6M | -25.9M | -22.7M |
| Capital Expenditure | 808K | 195K | 71.0K | 98.0K | 118K | 261K | 573K | 584K | 138K | 142K | 128K |
| Free Cash Flow | -9.19M | -10.8M | -11.5M | -15.8M | -17.9M | -50.7M | -48.4M | -31.0M | -38.7M | -26.1M | -22.9M |
| Ratios | |||||||||||
| ROE | - | -399.5% | -199.5% | -93.9% | -104.6% | -89.7% | -77.7% | -102.2% | -59.4% | -61.4% | -46.8% |
| ROA | -281.2% | -226.3% | -126.4% | -72.2% | -83.2% | -76.2% | -52.2% | -61.7% | -36.0% | -37.9% | -29.7% |
| Net Profit Margin | -388.4% | -304.5% | -240.8% | -234.6% | -388.7% | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% | -155.7% |
| Debt to Equity | - | - | - | 0.04x | 0.02x | 0.00x | 0.35x | 0.51x | 0.42x | 0.47x | 0.46x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DarioHealth Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 23.8M | 1.01 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Aug 28, 2025.
Who owns DarioHealth Corp
- Insiders 21.65%
- Institutions 9.41%
- Public & others 68.94%
- Shares outstanding 11.3M
- Free float 6.91M
Top funds holding DRIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 37.8K | 0.39% | +17.85% | Sep 2026 |
| iShares Micro-Cap ETF | 18.2K | 0.19% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 10.2K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 8.75K | 0.09% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 3.32K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.20K | 0.01% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 1.20K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 747.00 | 0.01% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 200.00 | 0.00% | 0.00% | Sep 2026 |
| Global Core Equity UCITS ETF USD Acc | 92.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding DRIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 1.22M | 12.47% | +100.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 65.7K | 0.67% | -0.36% | Jun 2026 |
| Geode Capital Management, LLC | 58.0K | 0.59% | -6.21% | Jun 2026 |
| BlackRock Inc | 37.8K | 0.39% | +100.85% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 37.4K | 0.38% | +24.33% | Jun 2026 |
| Citadel Advisors Llc | 24.3K | 0.25% | +18.71% | Jun 2026 |
| Northern Trust Corp | 13.2K | 0.14% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 3.32K | 0.03% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.00K | 0.03% | +200.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 1.90K | 0.02% | +189,900.00% | Jun 2026 |
| Royal Bank of Canada | 658.00 | 0.01% | +46.88% | Jun 2026 |
| Trust Co Of Toledo Na | 352.00 | 0.00% | 0.00% | Jun 2026 |
| ACTION POINT FINANCIAL PLANNING, LLC | 159.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 139.00 | 0.00% | -99.13% | Jun 2026 |
| SBI Securities Co Ltd | 69.00 | 0.00% | -2.82% | Jun 2026 |
| Barclays PLC | 26.00 | 0.00% | 0.00% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 10.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 9.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 5.00 | 0.00% | 0.00% | Jun 2026 |
DarioHealth Corp company profile
- Company name
- DarioHealth Corp
- Ticker
- DRIO.US
- Exchange
- USA Stocks
- Listed since
- Oct 6, 2014
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 160
- Fiscal year end
- December
- Address
- 322 W. 57th Street, New York, NY, United States, 10019
- Phone
- 972 4770 6377
- Website
- dariohealth.com
About DarioHealth Corp
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1. It also provides bundled full-suite or partial-suite subscriptions. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
DarioHealth Corp management
10- Ms. Chen Franco-YehudaCFO, Treasurer & Secretary · born 1984
- Mr. Steven C. NelsonConsultant · born 1973
- Dov OppenheimCo-Founder & Production Chief
- Lara DodoChief Operations Officer
- Zoe HarrisonVP of Accounting & Corporate Development
- Kat ParrellaInvestor Relations Manager
- Ms. Mona DeanChief Compliance Officer
- Claudia LeviContent & Communications Manager
- Mr. Rob HalpernSVP of Marketing
- Dr. Omar Manejwala M.D.Chief Medical Officer